Bali Muralidhar, Director at Reneo Pharmaceuticals, Inc. (RPHM), bought 14 shares at $9.50 ($133) on 2021-05-28, disclosed to the SEC on 2021-06-02.
Open-market purchase of $133 RPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| RPHM | BUY | 2021-06-25 | $384K | — | Filing → |
| RPHM | BUY | 2021-06-23 | $845K | — | Filing → |
| RPHM | BUY | 2021-06-10 | $315K | — | Filing → |